Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis

NCT04543409 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04543409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04543409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Terminated
Start date
September 22, 2020
Completion date
February 6, 2023
Enrollment
211 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic esophagitis